The 8th TransBioLine Consortium meeting took place in Sitges (Barcelona) on the 11th and 12th of April 2024. This 2-days hybrid meeting of the Consortium members included updates on all the organ Work Packages, discussions on project sustainability [...]
The TransBioLine consortium has been working for the past five years on discovery, validation and regulatory qualification of a variety of safety biomarkers for drug-induced organ injury. On Friday, February 9, 2024, the first Biomarker [...]
At the beginning of October, more than 40 members of TransBioLine participated in the 7th Consortium Meeting hosted by Roche in Basel (Switzerland). Only 15 months left until the project end, the main focus of [...]
TransBioLine work package 3 (WP3; drug-induced pancreatic injury; DIPI) applauds the recent Letter of Support issued by the FDA for DIPI safety biomarkers to the Critical Path Institute’s Predictive Safety Testing Consortium (PSTC). Within the [...]
On the 24th and 25th April, more than 50 representatives of TransBioLine partners had the opportunity to meet in Amsterdam during the 6th TransBioLine Consortium Meeting. After sharing the current financial status of the project [...]
On the 23rd of February, Sophia Samodelov, TransBioLine Project coordinator, participated in the closing meeting of eTRANSAFE Project “Towards a Quantum leap in drug safety assessment”. eTRANSAFE (enhancing translational safety assessment through integrative knowledge management) [...]
Millions of people with rheumatoid arthritis and psoriasis could benefit from Nottingham biomarker research. Nottingham researchers found its side effects are less likely than previously thought and are calling for guidelines affecting the use of [...]
On October 27th and 28th, the 5th Consortium Meeting of TransBioLine took place in Barcelona, where nearly 50 Consortium members met face to face for the first time after the pandemic. The 5th Consortium Meeting [...]
During year 3, clinical studies within the TransBioLine project are progressing in the enrolment of patients to move forward in the identification of novel biomarkers that reliably indicate specific organ injury during drug development. Status [...]
The FDA has decided to Accept the DILI Work Package into the Biomarker Qualification Program. We are very happy to have DIVI, DINI, DIKI and DILI already accepted by the FDA Biomarker Qualification Program! Take [...]
